A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer
- DOI
- 10.1007/s12282-020-01205-w
- Published
- 2021-02-27
- Container
- Breast Cancer
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s12282-020-01205-w,
title = {A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer},
author = {Junichi Kurebayashi and Eiichi Shiba and Tatsuya Toyama and Hiroshi Matsumoto and Minoru Okazaki and Tadashi Nomizu and Tohru Ohtake and Takaaki Fujii and Yasuo Ohashi},
year = {2021},
journal = {Breast Cancer},
doi = {10.1007/s12282-020-01205-w},
url = {https://doi.org/10.1007/s12282-020-01205-w}
}RIS
TY - JOUR TI - A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer AU - Junichi Kurebayashi AU - Eiichi Shiba AU - Tatsuya Toyama AU - Hiroshi Matsumoto AU - Minoru Okazaki AU - Tadashi Nomizu AU - Tohru Ohtake AU - Takaaki Fujii AU - Yasuo Ohashi PY - 2021 JO - Breast Cancer DO - 10.1007/s12282-020-01205-w UR - https://doi.org/10.1007/s12282-020-01205-w ER -
APA
Kurebayashi, J., Shiba, E., Toyama, T., Matsumoto, H., Okazaki, M., Nomizu, T., Ohtake, T., Fujii, T., & Ohashi, Y. (2021). A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer. https://doi.org/10.1007/s12282-020-01205-w
Source records
- crossref · retrieved 2026-09-26T08:34:13.821Z